(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 47.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Omniab's revenue in 2026 is $18,666,000.On average, 8 Wall Street analysts forecast OABI's revenue for 2026 to be $4,725,126,467, with the lowest OABI revenue forecast at $3,277,589,563, and the highest OABI revenue forecast at $6,840,980,071. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,640,890,453, with the lowest OABI revenue forecast at $4,100,534,128, and the highest OABI revenue forecast at $11,677,299,611.
In 2028, OABI is forecast to generate $8,669,005,772 in revenue, with the lowest revenue forecast at $5,476,837,971 and the highest revenue forecast at $13,073,873,024.